Emerging retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is sparking considerable excitement within the healthcare community. Early clinical studies have shown retatrutide peptide impressive reductions in physical mass and improvements in physiological markers for patients with excess weight . Scientists b